In 30-40% of the MPN subgroups essential thrombocythemia (ET) and myelofibrosis (MF), somatic mutations in the calreticulin gene (<i>CALR</i>) are drivers of the disease resulting in constitutive activation of the thrombopoietin receptor (MPL). Here, MPL is linked to myeloproliferative neoplasm.